Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

No drain, Same-Day discharge? new study tests safer parotid surgery

NCT ID NCT07620184

Symptom relief Sponsor: Uppsala University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether it is safe to remove a tumor from the parotid gland (a saliva gland near the ear) without using a surgical drain. Normally, a drain is placed to remove extra fluid, which often requires an overnight hospital stay. The researchers want to see if skipping the drain leads to similar complication rates and allows more people to go home the same day. About 600 adults having this surgery will be randomly assigned to get a drain or not, and their recovery will be tracked for six months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients scheduled to undergo partial or superficial parotidectomy without concurrent soft tissue surgery, in cases where a wound drain is traditionally used (extirpation of single adjacent lymph nodes is acceptable). * ASA physical status class 1-3. * Aged 18 years or older. * The patient understands the participant information and is able to make an informed choice. Exclusion Criteria: * Previous parotid surgery on the same side * Tumour with parapharyngeal extension. * Ongoing or planned perioperative treatment with tranexamic acid. * Ongoing treatment with dual antiplatelet therapy (single agent therapy, such as Aspirin or Clopidogrel, is not an exclusion criterion). * Ongoing treatment with anticoagulants (NOAC, Warfarin) at the time of surgery. NOAC must be discontinued at least 24 hours before surgery. * Ongoing treatment with low molecular weight heparin in doses higher than: Fragmin 5000 IU/day, Clexane 40 mg/day, or Innohep 4500 IU/day.Ongoing treatment for malignancy.Known coagulation disorder. * Platelet count \<150 x 10⁹ * PK-INR \>1.2. * Hb \<120 g/L. * APTT \>42s. * Preoperative impaired facial nerve function on the affected side (Sunnybrook Facial Grading System score \<90). * Supplementary postoperative treatment such as radiotherapy or extended surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parotid neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hematoma parotid gland cancer parotid gland neoplasm Postoperative Complications Seroma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parotid neoplasms Post operative complications Seroma as procedural complication

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Karolinska university hospital

    RECRUITING

    Stockholm, Sweden

  • NÄL

    RECRUITING

    Trollhättan, Sweden

  • Uppsala University Hospital, Department of Otorhinolaryngology

    RECRUITING

    Uppsala, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.